Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Ultragenyx CEO sells shares worth over $1.1 million

Published 09/05/2024, 11:57 AM
RARE
-

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has reported a significant transaction by Emil D. Kakkis, the company's President and CEO. On September 3, 2024, Kakkis sold 20,000 shares of common stock at a weighted average price of $55.85 per share, totaling over $1.1 million. This sale was part of a series of transactions with prices ranging from $55.02 to $57.55.

According to the SEC filing, following the sale, Kakkis still holds a substantial number of shares. Specifically, Kakkis retains direct ownership of 564,597 shares, which includes shares underlying RSUs subject to certain vesting conditions, as noted in the footnotes of the document. The shares sold were indirectly owned through the Emil Kakkis and Jenny Soriano Living Trust, established in 2009.

Investors often monitor insider transactions such as these for insights into executive sentiment regarding their company's stock. However, such sales and holdings do not necessarily signal a change in company strategy or outlook. The reasons for insider transactions can vary widely, including personal financial management.

Ultragenyx Pharmaceutical, based in Novato, California, specializes in the development of pharmaceutical preparations. The company's stock trades under the symbol RARE on the NASDAQ exchange. As always, investors are encouraged to consider the broader context of the market, the company's performance, and other relevant factors when evaluating insider transactions.

In other recent news, Ultragenyx Pharmaceutical Inc. reported a strong second quarter in 2024, with total revenue reaching $147 million, prompting an upward revision of its revenue guidance for the year. The company's earnings call underscored significant progress in its clinical pipeline and commercial portfolio, including favorable results from Phase III and Phase II trials for key drugs. Ultragenyx also achieved alignment with the FDA on a Phase III study design for GTX-102, a potential treatment for Angelman syndrome.

In the coming 6 to 18 months, Ultragenyx anticipates a series of regulatory marketing submissions and key clinical data readouts. However, the company's Wilson's disease program experienced a delay in its interim Stage 1 readout due to the need for additional observation time and data cleaning. Despite this, Ultragenyx remains positive about the commercial opportunity for GSDIa, hinting at a potential mid-$1 million price range.

Ultragenyx's GTX-102 for Angelman syndrome is reportedly the only program showing double-digit improvements in patients' conditions over an extended period. The company's gene therapy treatment for Wilson's disease could potentially replace standard care treatments and improve copper distribution in patients. Lastly, setrusumab for osteogenesis imperfecta shows promise in reducing pain and improving bone health through increased activity and exercise.

InvestingPro Insights

As Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) navigates the market, recent data from InvestingPro provides a snapshot of the company's financial health and stock performance. Despite the insider transaction by CEO Emil D. Kakkis, there are several indicators that may influence investor perception.

The company's market capitalization stands at $5.15 billion, reflecting its current valuation in the market. Ultragenyx has experienced a revenue growth of 19.47% over the last twelve months as of Q2 2024, showcasing an upward trajectory in sales. However, it's worth noting that the company has a negative gross profit margin of -49.52%, indicating that it spends more on the cost of goods sold than it earns in revenue, which is also reflected in an InvestingPro Tip highlighting the company's weak gross profit margins.

InvestingPro Tips suggest that analysts have revised their earnings estimates upwards for the upcoming period, which could signal optimism about the company's future performance. On the other hand, the same analysts do not anticipate Ultragenyx will be profitable this year, and the company has not been profitable over the last twelve months. This dichotomy between revenue growth and profitability is a critical point for investors to consider.

From a stock performance perspective, Ultragenyx is trading near its 52-week high, with the price at 95.15% of the peak, and it has seen a strong return over the last three months, amounting to 35.39%. This robust short-term performance may catch the attention of momentum investors.

For those looking to delve deeper into the company's metrics, InvestingPro offers additional insights. Currently, there are 11 more InvestingPro Tips available for Ultragenyx, which can be accessed for further analysis and investment decision-making.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.